Clinical Trial Update: Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients [Phase 2, Phase 3]

View source ↗

Summary

Dexmedetomidine is being studied in Phase 2 and Phase 3 trials to reduce agitation in critically ill patients with traumatic brain injury; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Conditions: Traumatic Brain Injury, Agitation,Psychomotor | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING